Health Policy Affairs

On Nov. 19, 2025, SIR together with American College of Cardiology, American College of Radiology, American Venous Forum, American Vein & Lymphatic Society, Outpatient Endovascular & Interventional Society, Society for Cardiovascular Angiography & Interventions, and Society for Vascular Surgery submitted a joint letter urging Aetna to revise its Varicose Veins Clinical Policy Bulletin (CPB 0050), which currently misclassifies cyanoacrylate closure (CAC) as experimental. CAC is an FDA-approved, guideline-recommended, standard-of-care treatment supported by extensive long-term evidence and widely covered by other major insurers. We request that Aetna align its coverage with current clinical guidelines to ensure patients have access to all medically appropriate treatment options.